ES2077796T3 - Sal cristalina de 4-(di-n-propil)amino-6-aminocarbonil-1,3,4,5-tetrahidrobenz(cd)indol. - Google Patents

Sal cristalina de 4-(di-n-propil)amino-6-aminocarbonil-1,3,4,5-tetrahidrobenz(cd)indol.

Info

Publication number
ES2077796T3
ES2077796T3 ES91301501T ES91301501T ES2077796T3 ES 2077796 T3 ES2077796 T3 ES 2077796T3 ES 91301501 T ES91301501 T ES 91301501T ES 91301501 T ES91301501 T ES 91301501T ES 2077796 T3 ES2077796 T3 ES 2077796T3
Authority
ES
Spain
Prior art keywords
amino
propil
tetrahidrobenz
indol
crystalline salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91301501T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Joseph Kress
David Lee Varie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2077796T3 publication Critical patent/ES2077796T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES91301501T 1990-02-26 1991-02-26 Sal cristalina de 4-(di-n-propil)amino-6-aminocarbonil-1,3,4,5-tetrahidrobenz(cd)indol. Expired - Lifetime ES2077796T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48518590A 1990-02-26 1990-02-26

Publications (1)

Publication Number Publication Date
ES2077796T3 true ES2077796T3 (es) 1995-12-01

Family

ID=23927224

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91301501T Expired - Lifetime ES2077796T3 (es) 1990-02-26 1991-02-26 Sal cristalina de 4-(di-n-propil)amino-6-aminocarbonil-1,3,4,5-tetrahidrobenz(cd)indol.

Country Status (28)

Country Link
US (1) US5397799A (enExample)
EP (1) EP0444852B1 (enExample)
JP (1) JP3157007B2 (enExample)
KR (1) KR100208114B1 (enExample)
CN (1) CN1027503C (enExample)
AT (1) ATE126506T1 (enExample)
AU (1) AU629453B2 (enExample)
BR (1) BR9100767A (enExample)
CA (1) CA2037099C (enExample)
CY (1) CY1887A (enExample)
DE (1) DE69112099T2 (enExample)
DK (1) DK0444852T3 (enExample)
ES (1) ES2077796T3 (enExample)
FI (1) FI95464C (enExample)
GR (1) GR3017940T3 (enExample)
HK (1) HK175495A (enExample)
HU (1) HU217118B (enExample)
IE (1) IE67801B1 (enExample)
IL (1) IL97306A (enExample)
LV (1) LV10251B (enExample)
NO (1) NO174149C (enExample)
NZ (1) NZ237181A (enExample)
PT (1) PT96852B (enExample)
RU (2) RU2034837C1 (enExample)
SG (1) SG69975A1 (enExample)
TW (1) TW219933B (enExample)
YU (1) YU47594B (enExample)
ZA (1) ZA911258B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302612A (en) * 1990-02-26 1994-04-12 Eli Lilly And Company 6-substituted-hexahydrobenz[cd]indoles
IL97309A (en) * 1990-02-26 1996-11-14 Lilly Co Eli Intermediates for hexahydrobenz Úcd¾ indoles and process for the preparation of pure enantiomers thereof
IL97308A (en) * 1990-02-26 1996-10-31 Lilly Co Eli 6-Substituted-hexahydrobenz (cd) indoles process for their preparation and pharmaceutical compositions containing them
US5364856A (en) * 1991-03-28 1994-11-15 Eli Lilly And Company 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz[CD]indoles
US5643934A (en) * 1991-03-28 1997-07-01 Eli Lilly And Company 6-heterocyclic-4-amino-1,2,2a,3,4,5-hexahydrobenz [CD]indoles
TW248556B (enExample) * 1993-01-18 1995-06-01 Takeda Pharm Industry Co
UA53205C2 (en) * 2002-04-03 2006-06-15 Pharmatech Close Joint Stock C Antidepressant formulation and method for its manufacture
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
NZ623002A (en) 2006-06-26 2015-08-28 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
CA2774039A1 (en) 2009-11-06 2011-05-12 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
CN103717214A (zh) 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
NO2686520T3 (enExample) 2011-06-06 2018-03-17
HUE066123T2 (hu) 2013-06-13 2024-07-28 Akebia Therapeutics Inc Készítmények és módszerek anémia kezelésére
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110339A (en) * 1977-11-25 1978-08-29 Eli Lilly And Company 4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole
US4576959A (en) * 1984-02-06 1986-03-18 Eli Lilly And Company 6-Substituted-4-dialkylaminotetrahydrobenz[c,d]indoles
US4745126A (en) * 1987-03-12 1988-05-17 Eli Lilly And Company Method of treating anxiety with tetrahydrobenz[c,d]indole-6-carboxamides
DE3809155A1 (de) * 1988-03-18 1989-09-28 Bayer Ag 1,3,4,5-tetrahydrobenz-(c,d)-indole
US5204340A (en) * 1989-04-11 1993-04-20 Eli Lilly And Company Tetrahydrobenz(c,d)indole serotonin agonists
US5229409A (en) * 1990-08-15 1993-07-20 Eli Lilly And Company 6-substituted-tetrahydrobenz[cd]indoles

Also Published As

Publication number Publication date
CN1054589A (zh) 1991-09-18
RU2034837C1 (ru) 1995-05-10
HK175495A (en) 1995-11-24
PT96852B (pt) 1998-07-31
CA2037099C (en) 2001-09-11
EP0444852A2 (en) 1991-09-04
ATE126506T1 (de) 1995-09-15
NO910735L (no) 1991-08-27
EP0444852A3 (en) 1992-02-19
SG69975A1 (en) 2000-01-25
IE910625A1 (en) 1991-08-28
TW219933B (enExample) 1994-02-01
JP3157007B2 (ja) 2001-04-16
GR3017940T3 (en) 1996-02-29
ZA911258B (en) 1992-10-28
BR9100767A (pt) 1991-10-29
NO910735D0 (no) 1991-02-25
IL97306A0 (en) 1992-05-25
AU629453B2 (en) 1992-10-01
YU47594B (sh) 1995-10-24
NO174149B (no) 1993-12-13
AU7197191A (en) 1991-08-29
FI95464C (fi) 1996-02-12
FI910895L (fi) 1991-08-27
DE69112099T2 (de) 1996-02-08
LV10251B (en) 1995-04-20
FI95464B (fi) 1995-10-31
KR910021375A (ko) 1991-12-20
HUT56542A (en) 1991-09-30
HU217118B (hu) 1999-11-29
PT96852A (pt) 1991-10-31
YU32791A (sh) 1994-01-20
LV10251A (lv) 1994-10-20
EP0444852B1 (en) 1995-08-16
IL97306A (en) 1996-10-16
NZ237181A (en) 1992-06-25
FI910895A0 (fi) 1991-02-25
CN1027503C (zh) 1995-01-25
DK0444852T3 (da) 1995-12-11
CY1887A (en) 1996-04-05
DE69112099D1 (de) 1995-09-21
IE67801B1 (en) 1996-05-01
CA2037099A1 (en) 1991-08-27
KR100208114B1 (ko) 1999-07-15
US5397799A (en) 1995-03-14
RU2083561C1 (ru) 1997-07-10
JPH04217662A (ja) 1992-08-07
NO174149C (no) 1994-03-23

Similar Documents

Publication Publication Date Title
RU94036004A (ru) Промежуточные соединения для получения ароматических аминоспиртовых производных
NO943762D0 (no) Indolderivater som 5-HT 1 agonister
CA2160966A1 (fr) Derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0245518A4 (en) ISOFLAVON COMBATINGS, SALTS AND ONCOSTATIC AND IMMUNE SUPPRESSIVE AGENTS.
FI931503A0 (fi) Indolderivat som antiallergiska och antiinflammatoriska aemnen
DK0393936T3 (da) 3-substituerede 2-oxindolderivater som antiinflammatoriske midler
FI944805A7 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
EP0544819A4 (en) Indole derivatives which inhibit leukotriene biosynthesis
AU629453B2 (en) Crystalline salt of 4-(di-n-propyl)amino-6-aminocarbonyl-1, 3,4,5-tetrahydrobenz(cd)indole
NO893078D0 (no) Indolderivater.
KR910700250A (ko) 인돌 유도체
FI915231A7 (fi) Mikrobiologinen menetelmä hydroksyloitujen pyratsiinijohdannaisten valmistamiseksi
ES2054823T3 (es) Agentes ansioliticos.
FI944727L (fi) Indolijohdannaisia 5-HT1:n kaltaisina agonisteina
AU3831495A (en) Indole derivatives useful as serotonergic agents
GR880100869A (el) Μέ?οδος παρασκευής παραγώγων υποκατεστημένου στυρολίου.
FI900641A7 (fi) Indolijohdokset
DE69320653D1 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
FI971492L (fi) Indolijohdannaiset 5-HT1-tyyppisinä agonisteina
ES2007265A6 (es) Un metodo para preparar conjugados de indol-portador biologicamente activos.
ES484022A1 (es) Un procedimiento para la preparacion de derivados de pirimi-do (1-6-a)indol
FI922710A0 (fi) Eliminering av aktiverade lymfocyter.
AU1275983A (en) Indolizino(8,7beta)indole derivatives
FI924769A7 (fi) Menetelmä substituoitujen indolien valmistamiseksi
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 444852

Country of ref document: ES